Ocular Therapeutix, Inc. beat EPS estimates 38% of the time across 16 reported quarters (6 beats, 10 misses), averaging -14.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.40 | $-0.35 | +12.5% | Beat | |
| Q1 FY26 | $-0.32 | $-0.41 | -28.1% | Miss | |
| Q4 FY25 | $-0.33 | $-0.29 | +12.1% | Beat | |
| Q3 FY25 | $-0.39 | $-0.37 | +5.1% | Beat | |
| Q2 FY25 | $-0.35 | $-0.39 | -11.4% | Miss | |
| Q1 FY25 | $-0.29 | $-0.37 | -27.6% | Miss | |
| Q4 FY24 | $-0.24 | $-0.29 | -20.8% | Miss | |
| Q3 FY24 | $-0.23 | $-0.26 | -13.0% | Miss | |
| Q2 FY24 | $-0.22 | $-0.24 | -9.1% | Miss | |
| Q1 FY24 | $-0.18 | $-0.24 | -33.3% | Miss | |
| Q4 FY23 | $-0.28 | $-0.28 | +0.0% | Beat | |
| Q3 FY23 | $-0.27 | $-0.51 | -88.9% | Miss |
Back to OCUL overview · OCUL holders · OCUL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.